April 26, 2025 06:00 AM EDT

Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Welcome back to Endpoints Weekly! Our team of reporters covered first-quarter earnings results from a handful of companies this week. See below for pharma executives� …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Earn­ings sea­son is up­on us; Makary on rare dis­ease; Start­up is first to in­ject CRISPR in the brain; and more

Editor

Senior Editor

Sign up to read this article for free.

Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more